Stockholder's Equity (Deficit) | Note 10 – Stockholders’ Equity (Deficit) Series C Preferred Stock On December 16, 2019, Diego Pellicer Worldwide sold 140,000 of its Series C Convertible Preferred Shares, with an annual accruing dividend of 10%, to Geneva Roth Remark Holdings, Inc. (“Geneva”), for $130,000 pursuant to a Series C Preferred Purchase Agreement with Geneva. To accommodate this transaction, Registrant’s Board of Directors approved and filed a certain Certificate of Designations with the Secretary of State of Delaware, designating 1,500,000 of its available preferred shares as Series C Preferred Convertible Stock, Stated Value of $1.00 per share, and with a par value of $0.0001 per share. This Certificate of Designations provides Registrant with the opportunity to redeem the Series C Shares at various increased prices at time intervals up to the 6-month anniversary of the closing and mandates full redemption on the 24-month anniversary. Geneva may convert the Series C Shares into Registrant’s common shares, commencing on the 6-month anniversary of the closing at a 30% discount to the public market price. The Company recorded a derivative liability of $165,218, valued using a Binomial Option Pricing Model, associated with Series C Preferred Shares. On December 31, 2019, the fair value of the conversion feature was a derivative liability of $190,131, valued using a Binomial Option Pricing Model, associated with Series C Preferred Shares. The Series C Preferred Stock is classified as temporary equity due to that the shares are immediately convertible at the option of the note holder. During the year ended Decembers 31, 2019, we recorded $8,750 accretion of discount. As of December 31, 2019, there were 140,000 shares outstanding and a discount of $131,250. The following assumptions were used in the Binomial Option Pricing Model in calculating the embedded conversion features and current liabilities for the year ended December 31, 2019. December 31, 2019 Risk-free interest rates 1.58 – 1.66 % Expected life (years) 1.95 – 2.00 Expected dividends 0 % Expected volatility 248-250 % Common Stock During the year ended December 31, 2019: During the year ended December 31, 2019, $842,712 of notes and $60,627 of accrued interest was converted into 48,684,667 shares of common stock and 434,783 shares were issued which were authorized as of December 31, 2018. A gain on extinguishment of debt of $159,233, extinguishment of debt discount of $233,571 and reduction of derivative liabilities of $940,382 have been recorded related to these conversions. As of December 31, 2019, 35,844 shares, valued at $35,844 for debt conversion were authorized, but not issued as of December 31, 2019. We issued 4,987,610 shares of common stock, valued at $170,348, for services. As December 31, 2019, 209,782 shares, valued at $11,598 for services were authorized, but not issued as of December 31, 2019, and included in stock to be issued in the accompanying condensed consolidated balance sheet. In connection with Debt Restructure Agreements dated on July 17, 2018, 675,759 shares of common stock were cancelled, valued at $108,121. We issued 24,566,400 shares of common stock, valued at $732,029 , for related party services. As December 31, 2019, 3,299,665 shares, valued at $79,817 for services were authorized, but not issued as of December 31, 2019. During the year ended December 31, 2019, 8,071,000 shares were issued for cashless warrant exercise. During the year ended December 31, 2019, we issued 5,000 shares for $2,648, which were authorized in prior period. During the year ended December 31, 2018: We sold 41,054 shares of common stock and received proceeds of $20,872. Additionally, 5,000 valued at $2,648 were not issued as of December 31, 2018. We issued 16,804 shares of common stock that were sold in 2017 and classified as shares to be issued at December 31, 2017. Holders of convertible notes converted $1,019,933 of notes and $78,107 of accrued interest into 15,230,423 shares of common stock valued at $2,726,567. Additionally, 85,110 shares, valued at $168,862, for the conversion of notes, were authorized but not issued as of December 31, 2018. 2,116,857 shares of common stock were returned in connection with Debt Restructure Agreements dated On July 17, 2018, additionally 675,759 shares of common stock, valued at $108,121, were agreed to be cancelled, has not been returned as of December 31, 2018. We issued 40,500 common shares as security for the payment of convertible notes. The shares, valued at $26,730 are held in escrow, are refundable and are recorded in a contra equity account. We issued 1,780,074 shares of common stock, valued at $618,532, for services. Additionally, 1,980,179 shares, valued at $322,433 for services, were authorized but not issued as of December 31, 2018. We issued 669,082 shares of common stock for payment of a former employee note in the amount of $166,354, plus accrued interest of $21,658. In addition, 273,245 excessive shares of common stock were issued, these shares are in the process of being cancelled. We issued 75,000 shares of common stock, valued at $47,254, to settle accounts payable to a consultant. We issued 125,000 shares of common stock, valued at $20,500, for an inducement of extension of sublease. We issued 2,308,938 shares of common stock, valued at $202,443 as share-based compensation to related parties. Additionally, 29,486 shares, valued at $95,983 were authorized to be issued for related party services, but were not issued as of December 31, 2018. As a condition of management employment, the Board of Directors approved employment agreements with two key executives. This agreement provided that additional shares will be granted each year at February 1 over the term of the agreement should their shares as a percentage of the total shares outstanding fall below prescribed ownership percentages. The CEO received an annual grant of additional shares each year to maintain his ownership percentage at 10% of the outstanding stock. The other two executives receive a similar grant to maintain each executive’s ownership percentage at 7.5% of the outstanding stock. During the year ended December 31, 2018, 2,732,106 shares were issued. At December 31, 2018, there is $229,031 accrued for the annual grants, representing 649,541 shares authorized not issued. The Company recorded compensation expense of $610,284 for the year ended December 31, 2018. Common stock warrant activity: The Company has determined that certain of its warrants are subject to derivative accounting. The table below provides a reconciliation of the beginning and ending balances for the warrant liabilities measured using fair significant unobservable inputs (Level 3) for the year ended December 31, 2019: Balance at December 31, 2018 $ 16,576 Issuance of warrants — Change in fair value during period (15,609 ) Balance at December 31, 2019 $ 967 The following assumptions were used in calculations of the Binomial Option Pricing Model for the periods ended December 31, 2019 and the Black-Scholes Option Pricing Model in calculating the embedded conversion features and current liabilities for the periods ended December 31, 2018. December 31, 2019 December 31, 2018 Annual dividend yield 0 % 0 % Expected life (years) 0.42 – 8.13 1.67 – 8.9 Risk-free interest rate 1.56 – 2.40 % 2.52 – 3.05 % Expected volatility 165 - 318 % 188 - 230 % The following represents a summary of all common stock warrant activity: Number of Weighted Average Weighted Average Balance outstanding, December 31, 2018 263,866 $ 12.04 3.62 Exercised (12,500 ) 2.95 2.55 Expired (39,540 ) 20.00 - Balance outstanding, December 31, 2019 211,826 $ 10.08 3.51 Exercisable, December 31, 2019 211,826 $ 10.08 3.51 Common stock option activity: The Company maintains an Equity Incentive Plan pursuant of which 124,000 shares of Common Stock are reserved for issuance thereunder. This Plan was established to award certain founding members, who were instrumental in the development of the Company, as well as key employees, directors and consultants, and to promote the success of the Company’s business. The terms allow for each option to vest immediately, with a term no greater than 10 years from the date of grant, at an exercise price equal to par value at date of the grant. As of December 31, 2019, 88,750 shares had been granted, with 10,000 of those shares granted with warrants attached. There remain 35,250 shares available for future grants. During the years ended December 31, 2019 and 2018, the Company recorded total option expense of $162,381 and $279,528, respectively. Unamortized stock option expense at December 31, 2019 is $86,606, which will be charged to expense in 2020. The aggregate intrinsic value of stock options outstanding at December 31, 2019 is $0. The following represents a summary of all common stock option activity: Number of Weighted Average Weighted Average Balance outstanding, December 31, 2018 294,959 $ 5.17 7.15 Granted — — Forfeited (122,480 ) 5.00 7.09 Balance outstanding, December 31, 2019 172,479 $ 5.29 5.47 Exercisable, December 31, 2019 162,479 $ 5.25 5.72 |